JP2020522544A - Ｐｃｓｋ９阻害剤の投与による糖尿病患者における高脂血症を治療する方法 - Google Patents

Ｐｃｓｋ９阻害剤の投与による糖尿病患者における高脂血症を治療する方法 Download PDF

Info

Publication number
JP2020522544A
JP2020522544A JP2019567608A JP2019567608A JP2020522544A JP 2020522544 A JP2020522544 A JP 2020522544A JP 2019567608 A JP2019567608 A JP 2019567608A JP 2019567608 A JP2019567608 A JP 2019567608A JP 2020522544 A JP2020522544 A JP 2020522544A
Authority
JP
Japan
Prior art keywords
patient
antibody
antigen
binding fragment
insulin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2019567608A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020522544A5 (enExample
Inventor
マーヤ・ブーヤス−ボバノヴィッチ
Original Assignee
サノフィ・バイオテクノロジー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by サノフィ・バイオテクノロジー filed Critical サノフィ・バイオテクノロジー
Priority claimed from PCT/IB2018/054182 external-priority patent/WO2018225041A1/en
Publication of JP2020522544A publication Critical patent/JP2020522544A/ja
Publication of JP2020522544A5 publication Critical patent/JP2020522544A5/ja
Priority to JP2023111915A priority Critical patent/JP2023123842A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21062—Subtilisin (3.4.21.62)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Endocrinology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Emergency Medicine (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Dermatology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
JP2019567608A 2017-06-09 2018-06-09 Ｐｃｓｋ９阻害剤の投与による糖尿病患者における高脂血症を治療する方法 Pending JP2020522544A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023111915A JP2023123842A (ja) 2017-06-09 2023-07-07 Ｐｃｓｋ９阻害剤の投与による糖尿病患者における高脂血症を治療する方法

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201762517672P 2017-06-09 2017-06-09
US62/517,672 2017-06-09
US201762532162P 2017-07-13 2017-07-13
US62/532,162 2017-07-13
EP18305565 2018-05-04
EP18305565.6 2018-05-04
PCT/IB2018/054182 WO2018225041A1 (en) 2017-06-09 2018-06-09 Methods for treating hyperlipidemia in diabetic patients by administering a pcsk9 inhibitor

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023111915A Division JP2023123842A (ja) 2017-06-09 2023-07-07 Ｐｃｓｋ９阻害剤の投与による糖尿病患者における高脂血症を治療する方法

Publications (2)

Publication Number Publication Date
JP2020522544A true JP2020522544A (ja) 2020-07-30
JP2020522544A5 JP2020522544A5 (enExample) 2021-07-26

Family

ID=62815099

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019567608A Pending JP2020522544A (ja) 2017-06-09 2018-06-09 Ｐｃｓｋ９阻害剤の投与による糖尿病患者における高脂血症を治療する方法
JP2023111915A Pending JP2023123842A (ja) 2017-06-09 2023-07-07 Ｐｃｓｋ９阻害剤の投与による糖尿病患者における高脂血症を治療する方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023111915A Pending JP2023123842A (ja) 2017-06-09 2023-07-07 Ｐｃｓｋ９阻害剤の投与による糖尿病患者における高脂血症を治療する方法

Country Status (9)

Country Link
EP (1) EP3634469A1 (enExample)
JP (2) JP2020522544A (enExample)
KR (1) KR20200026826A (enExample)
CN (1) CN110913889A (enExample)
AU (1) AU2018280567A1 (enExample)
CA (1) CA3066317A1 (enExample)
IL (2) IL271212B2 (enExample)
MX (1) MX2019014831A (enExample)
TW (2) TW201904608A (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3672B1 (ar) 2008-12-15 2020-08-27 Regeneron Pharma أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9).
MX347602B (es) 2011-01-28 2017-05-03 Sanofi Biotechnology Composiciones farmaceuticas que comprenden anticuerpos humanos frente a pcsk9.
AR087305A1 (es) 2011-07-28 2014-03-12 Regeneron Pharma Formulaciones estabilizadas que contienen anticuerpos anti-pcsk9, metodo de preparacion y kit
US10772956B2 (en) 2015-08-18 2020-09-15 Regeneron Pharmaceuticals, Inc. Methods for reducing or eliminating the need for lipoprotein apheresis in patients with hyperlipidemia by administering alirocumab
CN113876956B (zh) * 2020-07-01 2023-07-04 陈敏 Pcsk9抑制剂在制备促进皮肤色素生成产品中的应用
CN114525258A (zh) * 2020-10-30 2022-05-24 未来智人再生医学研究院(广州)有限公司 一种表达pcsk9阻断物的多能干细胞或其衍生物及应用
CN118076736A (zh) * 2021-09-30 2024-05-24 北京安龙生物医药有限公司 用于治疗与pcsk9相关疾病的靶向寡核苷酸
WO2023104051A1 (zh) * 2021-12-07 2023-06-15 广州嘉越医药科技有限公司 吲哚取代四氢异喹啉类化合物与他汀类化合物的联合应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3672B1 (ar) * 2008-12-15 2020-08-27 Regeneron Pharma أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9).
US20150283236A1 (en) * 2014-03-17 2015-10-08 Marie Baccara-Dinet Methods for treating subjects with primary hypercholesterolemia that is not adequately controlled
EP3753575A1 (en) * 2014-07-16 2020-12-23 Sanofi Biotechnology Methods for treating high cardiovascular risk patients with hypercholesterolemia using inhibitors of pcsk9
CA2955294A1 (en) * 2014-07-16 2016-01-21 Sanofi Biotechnology Methods for treating patients with heterozygous familial hypercholesterolemia (hefh)
US10772956B2 (en) * 2015-08-18 2020-09-15 Regeneron Pharmaceuticals, Inc. Methods for reducing or eliminating the need for lipoprotein apheresis in patients with hyperlipidemia by administering alirocumab

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
DIRK MULLERWIELAND, CARDIOVASC.DIABETOL, vol. VOL:16,NR:70, JPN5020007003, 25 May 2017 (2017-05-25), ISSN: 0004812357 *
HELEN M COLHOUN: "NO EFFECT OF PCSK9 INHIBITOR ALIROCUMAB ON THE INCIDENCE OF DIABETES IN A POOLED 以下備考", EUROPEAN HEART JOURNAL, vol. VOL:37, NR:39, JPN5020007004, 26 July 2016 (2016-07-26), pages 2981 - 2989, ISSN: 0004812358 *
LAWRENCE A LEITER: "LIPID-LOWERING EFFICACY AND SAFETY OF ALIROCUMAB IN PATIENTS WITH OR WITHOUT DIABETES: 以下備考", DIABETES, OBESITY AND METABOLISM, vol. VOL:19, NR:7, JPN5020007002, 16 February 2017 (2017-02-16), pages 989 - 996, ISSN: 0005005944 *

Also Published As

Publication number Publication date
RU2019144346A (ru) 2021-07-09
IL314423A (en) 2024-09-01
IL271212A (en) 2020-01-30
CN110913889A (zh) 2020-03-24
IL271212B1 (en) 2024-08-01
TW202310872A (zh) 2023-03-16
AU2018280567A1 (en) 2020-01-23
EP3634469A1 (en) 2020-04-15
KR20200026826A (ko) 2020-03-11
RU2019144346A3 (enExample) 2021-10-13
CA3066317A1 (en) 2018-12-13
IL271212B2 (en) 2024-12-01
MX2019014831A (es) 2020-02-13
TW201904608A (zh) 2019-02-01
JP2023123842A (ja) 2023-09-05

Similar Documents

Publication Publication Date Title
US20190031774A1 (en) Methods for treating hyperlipidemia in diabetic patients by administering a pcsk9 inhibitor
JP2023123842A (ja) Ｐｃｓｋ９阻害剤の投与による糖尿病患者における高脂血症を治療する方法
JP7559112B2 (ja) グルカゴン様ペプチド１受容体アゴニストおよびそれらの使用
EP3055333B1 (en) Use of a pcsk9 inhibitor to treat hyperlipidemia
EP3331908B1 (en) Anti-angptl8 antibodies and uses thereof
JP2022169718A (ja) Ｉｌ－４ｒアンタゴニストを投与することによりアレルギーを予防又は処置するための方法
JP7744190B2 (ja) リポタンパク質アフェレーシスを受けている高脂血症の患者を治療するための抗ｐｃｓｋ９阻害抗体
EP3169362B1 (en) Methods for treating high cardiovascular risk patients with hypercholesterolemia
AU2014274077A1 (en) Methods for treating autosomal dominant hypercholesterolemia associated with PCSK9 gain-of-function mutations
JP2017506626A (ja) 中程度用量スタチン療法により適切に管理されない高コレステロール血症を有する患者を処置するための方法
RU2772712C2 (ru) Способы лечения гиперлипидемии у пациентов с диабетом посредством введения ингибитора pcsk9
JP7789871B2 (ja) グルカゴン様ペプチド１受容体アゴニストおよびそれらの使用
ES2779126T3 (es) Uso de un inhibidor de PCSK9 para tratar hiperlipidemia
US20230272112A1 (en) Use of a pcsk9 inhibitor to treat homozygous familial hypercholesterolemia
HK40033729B (en) Use of a pcsk9 inhibitor to treat hyperlipidemia
HK40033729A (en) Use of a pcsk9 inhibitor to treat hyperlipidemia
EA045412B1 (ru) Агонисты рецептора глюкагоноподобного пептида 1 и их применения
HK1227890B (en) Use of a pcsk9 inhibitor to treat hyperlipidemia
HK1227890A1 (en) Use of a pcsk9 inhibitor to treat hyperlipidemia

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210607

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210607

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220628

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220926

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221128

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20230307